The Tyrosine Protein Kinase Receptor UFO pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase Receptor UFO pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Infectious Disease, Respiratory, and Genito Urinary System which include the indications Solid Tumor, Non-Small Cell Lung Cancer, Unspecified Influenza Virus Infections, Respiratory Syncytial Virus (RSV) Infections, Acute Respiratory Distress Syndrome, and Chronic Kidney Disease (Chronic Renal Failure). It also reviews key players involved in Tyrosine Protein Kinase Receptor UFO targeted therapeutics development with respective active and dormant or discontinued products.
The Tyrosine Protein Kinase Receptor UFO pipeline targets constitutes close to 50 molecules. Out of which, approximately 44 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 4, 9, 13, 1, 14, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 5, and 1 molecule.
Tyrosine Protein Kinase Receptor UFO overview
Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response.
For a complete picture of Tyrosine Protein Kinase Receptor UFO’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
